CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionCurrent ratio is 1.01×, lower than 95% of its Biotechnology peers (median 5.64×)
- FinancialsAltman Z-Score 3.72: safe zone
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.75%Above 5Y avg (0.41%)
Annual Rate
KRW 1200.00Paid annual
Payout Ratio
38.3%Sustainable
Payback Period
56.2 yr
Last Ex-Dividend
Sep 29, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
445.80BKRW315.64M · vs all stocks (USD)
Trailing P/E
28.85xvs Biotechnology peers
Revenue (TTM)
244.02BKRW172.78M · vs all stocks (USD)
Profit Margin
8.44%vs Biotechnology peers
Beta
0.4120xvs all stocks
52-Week Change
-42.47%vs all stocks
Market Capitalization
445.80BKRW315.64M · vs all stocks (USD)
Enterprise Value
588.38BKRW416.60M · vs all stocks (USD)
Trailing P/E
28.85xvs Biotechnology peers
Forward P/E
11.21xvs Biotechnology peers
PEG Ratio
0.1608xvs Biotechnology peers
Price to Sales (TTM)
1.94xvs Biotechnology peers
Price to Book (MRQ)
1.18xvs Biotechnology peers
Enterprise to Revenue
2.41xvs Biotechnology peers
Enterprise to EBITDA
15.22xvs Biotechnology peers
Gross Margin
68.82%vs Biotechnology peers
Profit Margin
8.44%vs Biotechnology peers
Operating Margin
12.15%vs Biotechnology peers
Return on Assets (TTM)
1.99%vs Biotechnology peers
Return on Equity (TTM)
4.78%vs Biotechnology peers
Revenue (TTM)
244.02BKRW172.78M · vs all stocks (USD)
Revenue per Share (TTM)
40.71KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
-5.10%vs Biotechnology peers
Gross Profit (TTM)
146.54BKRW103.75M · vs all stocks (USD)
EBITDA (TTM)
30.95BKRW21.91M · vs all stocks (USD)
Net Income (TTM)
19.61BKRW13.88M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
104.90%vs Biotechnology peers
Operating Cash Flow (TTM)
68.92BKRW48.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
18.66BKRW13.21M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.20KKRWUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.75%vs all stocks
5-Year Average Dividend Yield
0.41%vs all stocks
Payout Ratio
38.25%vs Biotechnology peers
Minority Interest (Equity)
2.44BKRWFY2025 · Dec 31, 2025Revenue
247.29BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
104.01BKRWFY2025 · Dec 31, 2025Gross Profit
143.28BKRWFY2025 · Dec 31, 2025Operating Income
17.01BKRW12.04M · vs all stocks (USD)
Pre-tax Income
6.58BKRWFY2025 · Dec 31, 2025Income Tax Expense
-9.08BKRWFY2025 · Dec 31, 2025Net Income
15.66BKRWFY2025 · Dec 31, 2025EBIT
7.23BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
30.95BKRWFY2025 · Dec 31, 2025Research & Development
29.19BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
62.42BKRWFY2025 · Dec 31, 2025Other Operating Expenses
4.45BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.40BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
649.39MKRWFY2025 · Dec 31, 2025EPS (Basic)
2.37KKRWFY2025 · Dec 31, 2025EPS (Diluted)
2.37KKRWFY2025 · Dec 31, 2025Basic Shares Outstanding
7.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
7.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.66BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
935.18MKRWFY2025 · Dec 31, 2025Operating Cash Flow
53.25BKRWFY2025 · Dec 31, 2025Free Cash Flow
38.27BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
48.89BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.66BKRWFY2025 · Dec 31, 2025Stock-based Compensation
-97.17MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-1.66BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
14.62BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
24.72BKRWFY2025 · Dec 31, 2025Capital Expenditures
-14.98BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-18.55BKRWFY2025 · Dec 31, 2025Net Acquisitions
-824.17MKRWFY2025 · Dec 31, 2025Purchase of Investments
-300.38MKRWFY2025 · Dec 31, 2025Sale of Investments
13.10BKRWFY2025 · Dec 31, 2025Other Investing Activity
172.06MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.83BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-4.69BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-4.69BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-13.15BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-8.92BKRWFY2025 · Dec 31, 2025Other Financing Charges
-8.62BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-40.01BKRWFY2025 · Dec 31, 2025Shares Outstanding
6.52MSharesUpdated Aug 19, 2026Float Shares
5.08MSharesUpdated Aug 19, 2026% Held by Insiders
18.63%vs all stocks
% Held by Institutions
6.82%vs all stocks
Total Cash (MRQ)
42.53BKRW30.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.53KKRWUpdated Aug 19, 2026Total Debt (MRQ)
125.33BKRW88.74M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3301xvs Biotechnology peers
Current Ratio (MRQ)
1.01xvs Biotechnology peers
Book Value per Share (MRQ)
58.10KKRWUpdated Aug 19, 2026Total Assets
581.76BKRW411.91M · vs all stocks (USD)
Total Current Assets
155.34BKRWFY2025 · Dec 31, 2025Total Liabilities
127.47BKRWFY2025 · Dec 31, 2025Total Non-current Assets
426.42BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
22.65BKRWFY2025 · Dec 31, 2025Total Current Liabilities
104.82BKRWFY2025 · Dec 31, 2025Cash
5.95MKRWFY2025 · Dec 31, 2025Cash Equivalents
48.89BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
48.89BKRWFY2025 · Dec 31, 2025Other Short-term Investments
50.00MKRWFY2025 · Dec 31, 2025Accounts Receivable
50.91BKRWFY2025 · Dec 31, 2025Inventory
43.07BKRWFY2025 · Dec 31, 2025Accounts Payable
1.80BKRWFY2025 · Dec 31, 2025Short-term Debt
57.12BKRWFY2025 · Dec 31, 2025Other Current Liabilities
62.37MKRWFY2025 · Dec 31, 2025Long-term Debt
19.51BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
110.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
3.65BKRWFY2025 · Dec 31, 2025Retained Earnings
435.87BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
454.29BKRW321.65M · vs all stocks (USD)
Treasury Stock
119.98BKRWFY2025 · Dec 31, 202552-Week Low
66.00KKRWUpdated Aug 19, 202652-Week High
141.10KKRWUpdated Aug 19, 202652-Week Change
-42.47%vs all stocks
Beta
0.4120xvs all stocks
50-Day MA
76.93KKRWUpdated Aug 19, 2026200-Day MA
106.51KKRWUpdated Aug 19, 2026Avg 10-Day Volume
20.81KSharesUpdated Aug 19, 2026Avg 30-Day Volume
22.60KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
2.37KKRWUpdated Aug 19, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.01×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 1.01Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Altman Z-Score 3.72: safe zoneNotable
Altman Z-Score: 3.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
The Marzetti Company
5 interpretationsHigh Retained Earnings With Profitability And EquityMulti-Year Revenue, Profit, And Income GrowthClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Equity
Naspers Limited
5 interpretationsHigh Retained Earnings With Profitability And EquityMinimal Tax and Interest DragCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Equity
Ovctek China Inc.
4 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Equity